These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35255965)

  • 21. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
    Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
    J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
    Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
    Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
    Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
    J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California.
    Herring AA; Kalmin M; Speener M; Goodman-Meza D; Snyder H; Campbell A; Moulin A; Shoptaw S
    J Subst Abuse Treat; 2021 Apr; 123():108260. PubMed ID: 33612194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes from the medication assisted treatment pilot program for adults with opioid use disorders in rural Colorado.
    Amura CR; Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Cook PF
    Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):1. PubMed ID: 34980179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
    Khan A; Khan Q; Kolb E
    J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient evaluation of a smartphone application for telehealth care of opioid use disorder.
    Bosse JD; Hoffman K; Wiest K; Todd Korthuis P; Petluri R; Pertl K; Martin SA
    Addict Sci Clin Pract; 2022 Sep; 17(1):50. PubMed ID: 36085078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder.
    Maricich YA; Gerwien R; Kuo A; Malone DC; Velez FF
    Hosp Pract (1995); 2021 Dec; 49(5):348-355. PubMed ID: 34461801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Communication between patients, peers, and care providers through a mobile health intervention supporting medication-assisted treatment for opioid use disorder.
    Flickinger TE; Waselewski M; Tabackman A; Huynh J; Hodges J; Otero K; Schorling K; Ingersoll K; Tiouririne NA; Dillingham R
    Patient Educ Couns; 2022 Jul; 105(7):2110-2115. PubMed ID: 35260260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safer in care: A pandemic-tested model of integrated HIV/OUD care.
    Eaton EF; Tamhane A; Turner W; Raper JL; Saag MS; Cropsey KL
    Drug Alcohol Depend; 2022 Feb; 231():109241. PubMed ID: 35007957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
    Marsden J; Tai B; Ali R; Hu L; Rush AJ; Volkow N
    Addiction; 2019 Aug; 114(8):1346-1353. PubMed ID: 30614096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
    DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
    Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attitudes, Beliefs, and Willingness Toward the Use of mHealth Tools for Medication Adherence in the Florida mHealth Adherence Project for People Living With HIV (FL-mAPP): Pilot Questionnaire Study.
    Morano JP; Clauson K; Zhou Z; Escobar-Viera CG; Lieb S; Chen IK; Kirk D; Carter WM; Ruppal M; Cook RL
    JMIR Mhealth Uhealth; 2019 Jul; 7(7):e12900. PubMed ID: 31271150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.